Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive ...
Achieve Life Sciences (ACHV) announced the outcome of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration. This meeting represents a key milestone in advancing cytisinicline’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback